Ovarian failure and permanent infertility occur in nearly all women of child-bearing age who are treated with myeloablative conditioning and allo-SCT. 1, 2 Recently, highly immunosuppressive but reduced-intensity conditioning regimens have enabled the engraftment of allogeneic cells and their resulting graft-versus-tumor effects. [3] [4] [5] However, the effect of reduced-intensity allo-SCT, or RIST, on the reproductive function of young women has not been examined. Here we report on two women who had successful pregnancies and childbirths after RIST for lymphoma.
Case 1: A 30-year-old woman presented at the age of 21 years with splenomegaly and was diagnosed with stage IVA follicular lymphoma. The disease progressed after treatment with two distinct multi-agent chemotherapy regimens, single-agent rituximab, single-agent alemtuzumab and splenectomy. At the age of 25 years she underwent partially HLA-mismatched RIST, and prophylaxis of GVHD with high-dose, post-transplantation CY, tacrolimus and mycophenolate mofetil (Figure 1) . 6 Pre-conditioning serum levels of estradiol and follicle-stimulating hormone were 173 pg/ ml and 9.6 mIU/ml, respectively, consistent with normal ovarian function. Full engraftment of donor cells was documented on day 30 after transplantation, and there was no evidence of GVHD. Normal menstrual periods resumed at 6 months after transplantation following 3 years of amenorrhea. At 4 years after transplantation she delivered a normal baby girl after an uncomplicated first pregnancy. Computed tomography scans of the chest, abdomen and pelvis at 1 month after delivery showed continuous CR of her lymphoma.
Case 2: A 28-year-old woman was diagnosed at the age of 25 years with stage IIB nodular sclerosis Hodgkin's lymphoma with an associated 16 Â 9 cm 2 mediastinal mass. The disease was refractory to three distinct regimens of multi-agent chemotherapy, but the mediastinal mass responded partially to radiation therapy. At the age of 26 years she underwent partially HLA-mismatched RIST using the same regimen as in Case 1. Pre-conditioning serum levels of estradiol and follicle-stimulating hormone were 58 pg/ml and 6.2 IU/ml, respectively, consistent with normal ovarian function. Full engraftment of donor cells was documented at 6 months after transplantation, and GVHD did not occur. Whole-body positron emission tomography/computed tomography scan showed no evidence of lymphoma at 16 months after transplantation. At 2 years after transplantation, the patient delivered her second child, a healthy baby girl, after a term pregnancy.
Premature and permanent ovarian failure is a common complication of allo-SCT. Fertility is most likely preserved in women who are pre-pubertal at the time of SCT or who are conditioned for transplantation with CY alone. 7 In contrast, successful pregnancy and childbirth occur in o2% of women who are post-pubertal at the time of transplantation and receive myeloablative conditioning with either BU or 410 Gy TBI. 7, 8 Hormone replacement therapy of women with ovarian failure after SCT has been associated with restoration of ovarian function and fertility. 9 Neither of the patients described here received hormone replacement therapy following transplantation, and ovarian function was retained or recovered spontaneously.
Compared with myeloablative allo-SCT, RIST from HLA-matched siblings is associated with reduced transplant-related morbidity and mortality. Encouraging outcomes have been reported in patients with a variety of hematologic malignancies including refractory Hodgkin's 10 or follicular lymphoma. 11 The women reported here lacked HLA-matched siblings and received partially HLAmatched RIST on clinical trials. Among 113 patients who received partially HLA-mismatched RIST more than 2 years ago at our institution, 40 were women and 17 were between the ages of 11 and 45 years. Seven of these 17 women are currently alive and disease-free, and two of them have had children. The results raise the possibility that fertility is preserved more often after RIST than after myeloablative allo-SCT. Detailed studies of ovarian function and fertility after RIST are needed to inform the riskbenefit decisions of young women contemplating allo-SCT for hematologic malignancies. 
